6 Houston health tech startups making major advancements right now

meet the finalists

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health. Photo courtesy Koda Health.

Home to leading hospitals, universities and health-focused incubators, Houston is a breeding ground for innovative medical technology and breakthroughs that can improve outcomes and lead to a better quality of life for patients.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Six forward-thinking businesses have been named finalists for the 2025 award. They range from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston Innovation.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Corveus Medical

Corveus Medical has developed a novel catheter device that allows cardiologists to perform a splanchnic nerve ablation, restoring the pressure balance in patients with moderate heart failure. Its pre-FDA-approved, minimally invasive solution deactivates a nerve that has been demonstrated to be a root cause behind heart failure progression, which allows physicians to treat patients who have traditionally had few options.

The company, formerly known as Caridian Medical, was founded in 2021 by CEO Tyler Melton and CMO Ishan Kamat. It has participated in incubators such as TMC Biodesign, Y Combinator, MedTech Innovator and Fogarty Innovation and was named one of the 10 most promising life science companies at Texas Life Science Forum in 2022. The company says it will move toward validation and verification testing for its device in Q4 of this year.

FibroBiologics

Regenerative medicine company FibroBioligics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells to repair tissue and modulate the immune system. The cell therapies offer treatments for chronic conditions such as degenerative disc disease, multiple sclerosis and non-healing wounds.

The publicly traded company was founded in 2021 by CEO Pete O'Heeron. It opened a new 10,000-square-foot Houston lab earlier this year to scale up research efforts and pave the way for in-house manufacturing. The company says it plans to launch its first clinical trial for diabetic foot ulcers soon, representing the transition of its fibroblast technology to the clinic setting.

Koda Health

Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. The company also added kidney action planning to its suite of services for patients with serious illnesses last year.

Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others.

NanoEar

NanoEar has miniaturized hearing aid technology so that it can be implanted across the eardrum, allowing adults with age-related hearing loss to enjoy better sound quality than they would with behind-the-ear hearing aids.

Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist, developed the technology, and the company was founded in 2016 with CFO Willem Vermaat and COO Michael Moore. The company participated in the TMC Innovation Institute in 2016. It has issued nine U.S. patents and performed successful human cadaver and animal proof-of-concept experiments. Its next step is developing a prototype.

Wellysis USA

Wellysis USA Inc. works to detect heart rhythm disorders with its continuous ECG/EKG monitor with AI reporting. Its S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge. The device weighs only 9 grams, is waterproof and designed to be comfortable to wear, and is considered to have a high detection rate for arrhythmias. It is ideally suited for patient-centric clinical trials to help physicians make diagnoses faster, cheaper and more conveniently.

It was established in Houston in 2023 and participated in the JLABS SFF Program the same year. It closed a $12 million series B last year. It was founded by CEO Young Juhn, CTO Rick Kim, CFO JungSoo Kim and chief strategy officer JoongWoo Kim.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

From Your Site Articles
Meagan Pitcher, CEO of Houston-based Bairitone Health. Photo courtesy of LinkedIn

6 female-founded startups shaping the Houston innovation ecosystem

meet the finalists

Female-founded businesses reached a new milestone last year. According to payroll company Gusto, female founders launched 49 percent of new businesses in 2024, reaching near parity with male-founded businesses for the first time.

And though they still face challenges, with access to VC funding at the top of the list, those women-led companies are driving major impact in the startup and innovation ecosystem.

The fifth-annual Houston Innovation Awards will honor six women-led startups that are shaping Houston innovation in our Female-founded Businesses category, presented by Houston Powder Coaters.

The finalists for the 2025 award, selected by our esteemed panel of judges, range from a company developing natural carbon-free fuel to another launching at-home sleep apnea technology.

Read more about these innovative startups and the visionary female founders behind them below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston innovation.

Anning Corporation

Clean energy company Anning Corporation is working to develop geologic hydrogen, a natural carbon-free fuel, using its proprietary stimulation approaches and advanced exploration modeling. The company said that geologic hydrogen has the potential to be the lowest-cost source of reliable baseload electricity in the U.S.

The company was founded by CEO Sophie Broun in 2024 and is a member of Greentown Labs. Last month, it also announced that it was chosen to participate in Breakthrough Energy’s prestigious Fellows Program. Anning raised a pre-seed round this year and is currently raising a $6 million seed round.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Brain Haven

Founded at the University of Houston, Brain Haven is developing neuroscience-based, clinically validated protocols that use sensory stimulation through smell and sound to offer a natural and non-invasive way to activate the brain and preserve neuroplasticity. The company aims to deliver an accessible and affordable way for the aging population to preserve memory, delay cognitive decline and improve quality of life.

The company was co-founded by Gail Aflalo, a graduate student in the University of Houston College of Optometry, and Jokūbas Žiburkus, an associate professor in the department of biology and biochemistry at UH. It was selected to participate in the 2024 Innov8 Cohort, where it won the cohort's Startup Pitch Day, and was included in Class 13 of UH RED Labs. Brain Haven was awarded $70,000 in seed funding from UH in June 2025 to support a year-long research initiative in adults aged 50 and above.

FlowCare

Sugar Land-based FlowCare is developing a period health platform that integrates smart dispensers, education and healthcare into one system to make free, high-quality organic period products more accessible.

The company was founded by CEO Tanu Jain, a registered nurse and product management executive, in 2024. It participated in the TiE Women Program and the Houston Community College Business Plan Competition, placing in the top five in both pitch competitions.

March Biosciences

Houston cell therapy company March Biosciences aims to treat unaddressed challenging cancers, with its MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma, currently in Phase 2 clinical trials.

The company was founded in 2021 by CEO Sarah Hein, Max Mamonkin and Malcolm Brenner and was born out of the TMC Accelerator for Cancer Therapeutics. The company completed a $29.6 million series A last year and also raised a $4.2 million seed round.

TrialClinIQ

Houston-based TrialClinIQ is an AI-powered clinical trial recruitment platform that helps identify, qualify and enroll eligible patients in appropriate trials faster and more accurately.

The company was founded in 2025 by CEO Jontel Pierce and Janette Obi.

-----

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

This week's roundup of Houston innovators includes Phillip Yates of Equiliberty, Meagan Pitcher of Bairitone Health, and Moody Heard of Builtforce. Photos courtesy

3 Houston innovators to know right now

who's who

Editor's note: InnovationMap regularly introduces its readers to a handful of Houston innovators recently making headlines with news of innovative technology, investment activity, and more. Our first January batch includes three innovators across social impact, health care, and more.

Phillip Yates, CEO of Equiliberty

Phillip Yates joins the Houston Innovators Podcast to share why 2025 is the year of launch for Equiliberty. Photo courtesy of Equiliberty

For Phillip Yates, this year will be the year of launch. The attorney-turned-entrepreneur has been working on his fintech platform, Equiliberty, for years now, but come the first half of 2025, it's go time.

"We're going to release our technology in Q2 of this year, and we're looking to commercialize it by the end of this year," Yates says on the Houston Innovators Podcast.

The platform connects users with resources to build wealth. Yates, along with his co-founders, Rachel Howard and Cody Bailey, created the company with the mindset that people with lower financial means can take control of their own financial success — in a way that doesn't take away from anyone else. Continue reading.

Meagan Pitcher, co-founder and CEO of Bairitone Health

Meagan Pitcher, co-founder and CEO of Bairitone Health, joins the Houston Innovators Podcast. Photo courtesy of Bairitone

There's a slew of treatment options for people living with sleep apnea. But, the bigger problem, as Meagan Pitcher realized during her time at the Texas Medical Center's Biodesign program, is that there's no easy way to reliably diagnose and determine a treatment plan for patients.

"We saw all of the companies trying to solve the problem of making the airway collapse less or make the air way wider — it might be surgery, might be medication, or nerve stimulation," Pitcher says on the Houston Innovators Podcast. "One of the things we found was that it was really hard to match a patient with sleep apnea with a good treatment for them. One of the reasons is it's hard to get an understanding of where the individual's site of collapse is as sleep medicine is currently practiced."

As Pitcher went through the TMC Biodesign program, she teamed up with her co-founders — CTO Onur Kilicand and CMO Britt Cross — to find a solution, and together they developed Bairitone Health. The company's technology provides at-home medical imaging using sonar sensing. The non-invasive device has the potential to replace the current standard of care, which is a surgical procedure. Continue reading.

Moody Heard, CEO of BuildForce

Houston-based Buildforce is developing a technology to better connect contractors and the trade professionals they employ. Photo courtesy of Buildforce

Houston-based Buildforce announced it has acquired Ladder, which is a Y Combinator-backed, technology-enabled construction labor marketplace.

The acquisition is part of Buildforce’s expansion plans into the southeastern U.S. and during a time of increased demand for skilled construction talent. Buildforce will work to leverage the Ladder customer base of over 200 customers across six states, as well as its extensive electrician network of over 10,000 pre-screened electricians, which is the largest in the Southeast.

“There are two major problems plaguing the construction labor market,” Moody Heard, co-founder and CEO of Buildforce, says in a news release. “One, the project-based nature of construction work means tradesmen are constantly ‘working themselves out of a job’, meaning high employee turnover. And two, the industry is experiencing a secular decline in the supply of tradesmen relative to surging demand.” Continue reading.

Meagan Pitcher, co-founder and CEO of Bairitone Health, joins the Houston Innovators Podcast. Photo courtesy of Bairitone

Promising Houston sleep tech startup readies for big year of growth, work toward FDA clearance

HOUSTON INNOVATORS PODCAST EPISODE 268

There's a slew of treatment options for people living with sleep apnea. But, the bigger problem, as Meagan Pitcher realized during her time at the Texas Medical Center's Biodesign program, is that there's no easy way to reliably diagnose and determine a treatment plan for patients.

"We saw all of the companies trying to solve the problem of making the airway collapse less or make the air way wider — it might be surgery, might be medication, or nerve stimulation," Pitcher says on the Houston Innovators Podcast. "One of the things we found was that it was really hard to match a patient with sleep apnea with a good treatment for them. One of the reasons is it's hard to get an understanding of where the individual's site of collapse is as sleep medicine is currently practiced."

As Pitcher went through the TMC Biodesign program, she teamed up with her co-founders — CTO Onur Kilicand and CMO Britt Cross — to find a solution, and together they developed Bairitone Health. The company's technology provides at-home medical imaging using sonar sensing. The non-invasive device has the potential to replace the current standard of care, which is a surgical procedure.



This year, the company joined Activate Houston's inaugural cohort as the lone biotech company. Activate, which announced its expansion to Houston in 2023, helps hardtech founders develop and grow their companies from bench to commercialization, though it mostly focuses on industrial or climatetech innovators. In addition to this accomplishment, Bairitone Health was among the 2024 Houston Innovation Awards finalists.

While 2024 was successful for the company, next year should bring even more milestones for Bairitone, Pitcher says, including a seed round of funding that will support the growth of their team, fund early testing, and fuel Baritone's path toward FDA clearance.

"2025 is going to be a big year for Bairitone, especially around solidifying our regulatory plan. The device we're making is really low risk — we're not putting anything into the body, and we're potentially replacing a surgical procedure," Pitcher says. "We've always hypothesized that we'll have a 510(k) clearance with the FDA, but we're moving toward having our first meeting with the FDA to solidify those plans."

Bairitone's journey so far has been a uniquely Houston story, as Pitcher acknowledges.

"I really love Houston — especially for med tech. The medical center is just awesome, you have all these brilliant people coming in from the entire world to work at these institutions," Pitcher says. "It's kind of because of this atmosphere of excellence around health care, innovation, open mindedness, and collaboration — those are reasons why I really love working in Houston."

The inaugural Activate Houston cohort has 11 fellows across energy, materials, life sciences, space, and other sectors. Photo via activate.org

Hardtech fellowship names 11 innovators to inaugural Houston cohort

ready for activation

A national hardtech-focused organization has named its 2024 batch of innovators, which includes the inaugural Houston-based cohort.

Activate named 62 fellows and 50 companies for is latest class, which spans Berkley, California — where the organization is based, Boston, New York, and Houston. Additionally, Activate Anywhere, the program's virtual and remote cohort, was named. According to Activate, it received over 1,000 applicants.

“People, not ideas alone, move the world forward. It is through the drive and determination of brilliant scientists and engineers that we are witnessing true progress,” says Activate CEO Cyrus Wadia in a news release. “Our current Activate Fellows and alumni are already pioneering innovative solutions that make a measurable difference. We’re thrilled to support the next 62 visionaries who will lead the charge in addressing our most urgent issues through groundbreaking science and technology.”

It's the first year Activate has hosted a Houston-based cohort. The organization initially announced its expansion early last year. The inaugural cohort has 11 fellows across energy, materials, life sciences, space, and other sectors.

The named Houston fellows selected for the 2024 class include:

  • Krish Mehta, founder and CEO of Phoenix Materials, a company that decarbonizes concrete using industrial waste.
  • Gabriel Cossio, founder and CEO of Nanoscale Labs, which is developing a high-throughput and low-cost nanomanufacturing system.
  • Matthew McDermott, founder and CEO of Refound Materials, a materials technology company developing more efficient synthesis recipes for accelerated materials discovery.
  • Alec Ajnsztajn, founder and CEO of Coflux Purification, a company that's creating a product that allows industries and water providers to cheaply remove forever chemicals to provide safe drinking water at a fraction of current energy use.
  • Ryan DuChanois and Yang Xia , co-founders of Solidec, a Houston-based startup redefining chemical manufacturing.
  • Meagan Pitcher, co-founder and CEO of Bairitone Health, which brings advanced imaging diagnostics into the home environment.
  • Wei Meng, co-founder and CEO of LumiStrain, a startup offering novel technology for mechanical strain mapping.
  • Sonia Dagan of Atolla Tech, which is developing a lidar and machine-learning algorithm for identifying and quantifying airborne insects.
  • Rodrigo Alvarez-Icaza, founder and CEO of Elysium Robotics, a company that's replacing electric motors with muscle-like actuators to enable massive deployment of highly capable and low-cost robotic systems.
  • Blake Herren, CEO and Co-founder of Raven Space Systems, which is modernizing composite manufacturing with 3D printing and Industry 4.0 solutions to build the factories of the future.

------

This article originally ran on EnergyCapital.

This year, seven of the 10 most-promising life science companies are based in Houston. Photo courtesy of Rice Alliance

Houston startups dominate ‘most-promising’ companies announcement at annual event

on the list

Rice University played host this week to the 12th annual Texas Life Science Forum, where life science leaders and startup founders could network, learn and present pitches on their solutions to a wide array of health-related issues.

Hosted by Rice Alliance for Technology and Entrepreneurship and BioHouston on November 7, the event brought together more than 600 attendees for a series of keynote speakers and panels. This year, 45 early-stage therapeutic, diagnostic, medical device and digital health companies—many of which are based in Houston—also pitched their concepts.

Fort Worth-based AyuVis Research walked away from the event with the two top recognitions: The Michael E. DeBakey Memorial Life Science Award and the People's Choice Award. The company, which has developed a small molecule immunotherapy targeting bronchopulmonary dysplasia (BPD) in preterm neonates and other respiratory disorders. The company is raising a $20 million Series A round to support its clinical development and is slated to pitch at IGNITE Health’s Fire Pitch 2023 today, November 9, at the Ion.

Each year the Rice Alliance and BioHouston also name its 10 most promising life science companies, selected by investors—seven out of 10 of which are based in Houston. This year's selection included the following companies, in alphabetical order:

  • 7 Hills Pharma: This Houston-based clinical stage immunotherapy company has developed the concept of allosteric activation of integrins to facilitate cell adhesion and promote immune responses. The concept has uses in preventing infection and cancer, and increasing the effectiveness of oncology drugs and infectious disease vaccines.
  • Bairitone Health: This Houston-based company is building a scalable diagnostic system for sleep apnea anatomy utilizing home-use wearable, passive Sonar technology and AI techniques.
  • Diakonos Oncology: Also based in Houston, Diakonos' Dendritic Cell Vaccine was awarded the FDA’s Fast Track designation. The clinical-stage biotech company's immunotherapies have shown early successes for hard-to-reach, aggressive cancers like Glioblastoma Multiforme.
  • Mongoose Bio: With more than 20 years of research, Mongoose specializes in T cell-based therapies for diverse solid tumors TCR-based therapies in cancer patients. The Houston-based company has developed an immunopeptidome discovery platform for TCR-based therapies in cancer patients.
  • Nandi Life Sciences: Nandi is developing antibodies for Avastin-resistant ovarian cancer, with
  • further application in breast, colorectal and lung cancer. The company is based out of Texas Medical Center Innovation.
  • NKILT Therapeutics: This Houston-based company's seed-stage cell therapy has applications in solid tumors, such as colorectal cancer, ovarian cancer, clear cell renal carcinoma, endometrial
  • cancer and more. It is developing a novel and proprietary Chimeric ILT-Receptor.
  • NuVision Biotherapies: Based in the United Kingdom, NuVision has developed and proven a treatment for dry eye disease. It's known for its Omnigen and OmniLenz products and is raising a series A to scale, take the business to profitability and exit.
  • Panakeia Technologies: Also based in the UK, Panakeia has developed an AI-based software that can provide multi-omic biomarkers in minutes. Currently this process takes days or weeks. It's RuO platform can identify 4,500 known multi-omics cancer markers.
  • Taurus Vascular: A recent spin-out of the Texas Medical Center Innovation Biodesign program, Taurus is developing a novel, catheter-based solution for treating endoleaks, which can be related to aortic aneurysms.
  • YAP Therapeutics: The only California-based company to make the cut, this preclinical-stage biotech develops genetic medicines that leverage the company’s tissue renewal and regeneration platform to reverse and cure severe diseases, including heart failure, pulmonary diseases, retinal degeneration and hearing loss.

Last year, Bairitone Health took home the DeBakey and People's Choice awards.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
View All Listings